1. Home
  2. NUVL vs PCOR Comparison

NUVL vs PCOR Comparison

Compare NUVL & PCOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$104.60

Market Cap

8.3B

Sector

Health Care

ML Signal

HOLD

PCOR

Procore Technologies Inc.

HOLD

Current Price

$53.16

Market Cap

8.4B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUVL
PCOR
Founded
2017
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
8.3B
8.4B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
NUVL
PCOR
Price
$104.60
$53.16
Analyst Decision
Strong Buy
Buy
Analyst Count
16
16
Target Price
$134.75
$74.19
AVG Volume (30 Days)
506.3K
2.6M
Earning Date
05-08-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
6.94
EPS
N/A
N/A
Revenue
N/A
$1,322,509,000.00
Revenue This Year
N/A
$15.24
Revenue Next Year
$1,239.49
$12.99
P/E Ratio
N/A
N/A
Revenue Growth
N/A
14.83
52 Week Low
$70.25
$46.08
52 Week High
$113.02
$82.32

Technical Indicators

Market Signals
Indicator
NUVL
PCOR
Relative Strength Index (RSI) 53.04 44.98
Support Level $97.91 $46.97
Resistance Level $107.49 $58.70
Average True Range (ATR) 3.83 2.45
MACD -0.18 -0.22
Stochastic Oscillator 56.63 12.01

Price Performance

Historical Comparison
NUVL
PCOR

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About PCOR Procore Technologies Inc.

Procore Technologies Inc is a cloud-based construction management software company. It generates revenue through subscriptions for access to its software products. The company's products include Design Coordination, BIM, Field Productivity, Project Financials, Invoice Management, Portfolio Financials, Capital Planning, Accounting Integrations, and Analytics. The software products are hosted on its cloud-based SaaS construction management platform. Subscriptions are sold for a fixed fee and revenue is recognized ratably over the term of the subscription.

Share on Social Networks: